A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects less than 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2013
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 01 Aug 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Feb 2013 New trial record